Asset profile
QR12000
Small molecule
Evidence outlook · registrational
Hypertension: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT07700875: The study was a randomized, quadruple-masked, active-controlled trial with 391 participants and a clinical hypertension endpoint: change in mean sitting systolic blood pressure at Week 8. Because the registry provides no primary-endpoint results, the outcome is unknown and the trial cannot be rated as strong evidence despite its robust design.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.